The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory follicular lymphoma or R/R diffuse large B-cell lymphoma, after two or more lines of systemic therapy.
Hodgkin lymphoma has long been a model disease in the field of oncology—one of the first diseases we learned to cure with radiation and ultimately chemotherapy.
